Triple-Drug attack before surgery aims to wipe out High-Risk prostate cancer
NCT ID NCT07027124
First seen Mar 22, 2026 · Last updated May 16, 2026 · Updated 6 times
Summary
This study tests whether giving a mix of hormone therapy (ADT), a targeted drug (darolutamide), and an immunotherapy (pembrolizumab) before prostate removal surgery, followed by more immunotherapy after surgery, can reduce or eliminate cancer in high-risk prostate cancer patients. About 40 men with aggressive, non-spread prostate cancer will take part. The goal is to see if this approach leads to very little or no cancer left at the time of surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Icahn School of Medicine at Mount Sinai
RECRUITINGNew York, New York, 10028, United States
Contact
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.